Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.
Pubmed ID: 25280124
Pubmed Central ID: PMC4268385
Journal: Journal of thrombosis and haemostasis : JTH
Publication Date: Dec. 1, 2014
MeSH Terms: Humans, Male, Adult, Female, Aged, Risk Factors, Adolescent, Middle Aged, Proportional Hazards Models, Anemia, Sickle Cell, Genotype, Young Adult, Incidence, Retrospective Studies, Venous Thromboembolism, Pulmonary Embolism
Grants: K01 HL108832, K12 HL087169, 1K01HL108832-01, 2K12HL087169-06, K08 HL125100
Authors: Naik RP, Streiff MB, Haywood C, Segal JB, Lanzkron S
Cite As: Naik RP, Streiff MB, Haywood C Jr, Segal JB, Lanzkron S. Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost 2014 Dec;12(12):2010-6. Epub 2014 Oct 18.
Studies:
Abstract
BACKGROUND: Venous thromboembolism (VTE) has been recently recognized as a complication of sickle cell disease (SCD); however, the incidence of VTE in SCD is unknown. OBJECTIVES: The primary objective of this study was to determine the incidence of first VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT), among SCD patients age ≥ 15 years. We also evaluated genotypic differences in VTE risk and determined the relationship between VTE and mortality. PATIENTS/METHODS: In this retrospective cohort study, we used data from the Cooperative Study of Sickle Cell Disease (CSSCD) to calculate incidence rates for first VTE. We used Cox proportional hazard models to estimate hazard ratios (HRs) for time to VTE by genotype and time to death by VTE status. RESULTS: We included 1523 SCD patients aged ≥ 15 years with 8862 years of follow-up in this analysis. The incidence rate for first VTE was 5.2 events/1000 person-years (95% confidence interval [CI] 3.8-6.9) with a cumulative incidence of 11.3% (95% CI 8.3-15.3) by age 40 years. Individuals with the SS/Sβ(0) -thalassemia genotype had the highest rate of VTE (7.6 events/1000 person-years [95% CI 5.3-10.6]). The incidence of PE exceeded that of isolated DVT (3.6 [95% CI 2.5-5.1] events/1000 person-years vs. 1.6 [95% CI 0.9-2.7] events/1000 person-years), although this difference was not statistically significant. SCD patients with VTE had a higher mortality rate (adjusted HR 2.32 [95% CI 1.20-4.46]) than those without VTE. CONCLUSIONS: Patients with SCD are at substantial risk for VTE, and individuals with VTE are at higher risk of death than those without VTE.